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Abstract
Background: The measurement of Interferon gamma or Interferon gamma inducible protein (IP)-10 in antigen stimulated
blood samples is suggested as an alternative method for latent tuberculosis (TB) diagnosis. Nonetheless, their role in active
TB diagnosis, particularly in TB endemic settings is yet to be defined. In this study, the sensitivities and specificities of
Interferon gamma release assay (IGRA), IP-10 assay and tuberculin skin test (TST) in detecting active TB cases were assessed
in human immunodeficiency virus (HIV) sero-negative TB patients and healthy controls respectively.
Methods/Principal Findings: A total of 177 adult TB patients and 100 healthy controls were included for this study.
QuantiFERON-TB Gold In-tube (QFT-IT) method was used to analyze the sensitivity and specificity of IGRA. QFT-IT, IP-10 and
TST yielded the diagnostic sensitivities of 90.6% (95%CI: 86.3%–94.9%), 92.5% (95%CI: 88.6%–96.4%) and 68.9% (95%CI:
60.6%–77.2%) and specificities of 55% (95% CI: 35.2%–54.8%), 48% (95% CI: 38.2%–57.8%) and 75.5% (95% CI: 66.8%–
84.2%), respectively. The extent of pulmonary involvement or presence of diabetes mellitus did not appear to influence the
sensitivities of any of these tests. The combination of any of the two tests among QFT-IT, IP-10 and TST showed .98%
sensitivity among smear negative cases and particularly the combination of IP-10, TST and smear microscopy showed 100%
sensitivity, however, the specificity was decreased to 44.8%.
Conclusions/Significance: QFT-IT and IP-10 were highly sensitive in detecting active TB cases. The combination with TST
improved the sensitivity of QFT-IT and IP-10 significantly. Although the higher sensitivity of combination of QFT-IT/IP-10 and
TST may be useful in active TB diagnosis, they are limited by their poor specificity due to the high prevalence of latent TB in
our settings.
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Introduction
Tuberculosis (TB) remains the single infectious disease, causing
the highest mortality in humans, leading to 3 million deaths
annually, about five deaths every minute [1]. The alarming increase
in morbidity and mortality due to TB indicates the need to
strengthen control measures. Control of this disease depends largely
on early detection and treatment of active cases. Smear microscopy
and nucleic acid amplification test are the two currently available
rapidconfirmatorytestsforactiveTBdisease diagnosis,butbothare
limited by their poor sensitivity [2,3]. Another confirmatory test for
active TB disease is culturing the mycobacterium, but it requires
several weeks to obtain the results [2].
A recent break through in TB diagnosis is the introduction of
interferon gamma release assay (IGRA) in which the production of
interferon gamma (IFN-c) in response to Mycobacterium tuberculosis
specific antigens is measured. Three commercial kits based on the
IGRA principle are available: T-SPOT.TB, QuantiFERON-TB
Gold, QuantiFERON-TB Gold in-tube (QFT-IT). T-SPOT.TB
and QuantiFERON TB Gold assays use only Early Secretory
Antigenic Target (ESAT)-6 and Culture Filtrate Protein (CFP)-10,
whereas an additional antigen TB 7.7 is incorporated in
QuantiFERON kits. The currently available data suggest that
IGRAs are less influenced by prior BCG vaccination and
environmental mycobacteria [4]. Though IGRAs are offered for
latent TB diagnosis (LTBI), studies are ongoing to define their role
in diagnosis of active TB disease too.
The sensitivity of IGRAs is reported to be higher in detecting
active TB patients in low TB endemic countries [5–11]. A recent
study conducted in urban hospitals in United Kingdom using
ELISPOT, reported that IGRA in combination with TST can be
used to rule out the suspicion of active TB disease among
clinically suspected subjects [12]. However, the data from high
TB endemic countries are limited. Thus, further studies are
needed to validate the role of IGRA in the diagnosis of TB in
high endemic settings.
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9051The data available from high TB endemic countries clearly
evidence that sensitivity of IGRA is relatively lower in low TB
endemic countries [13–16]. In this situation, various attempts have
been made to enhance the sensitivity of IGRA and one of them is
evaluating additional or alternative biomarkers.
Earlier studies conducted to identify the new diagnostic markers
suggest that IFN-c inducible protein (IP)-10 is a potential
biomarker for TB diagnosis [11,17–20]. IP-10 is a pro-inflamma-
tory chemokine, expressed by monocytes and macrophages [21].
Upon contact with viral or bacterial agents, antigens or mitogens,
the pro-inflammatory cytokines like IFN-c stimulates expression of
IP-10 [22–24]. However, none of the studies have been conducted
in high endemic settings to compare the sensitivity and specificity
of IGRA and IP-10 assays for active TB diagnosis.
In this study, we aimed to assess the sensitivities and specificities
of QFT-IT, IP-10 and tuberculin skin test (TST) among human
immunodeficiency virus (HIV) negative individuals to define their
role in active TB diagnosis in our settings, where TB is endemic.
Materials and Methods
Study Participants
This study was approved by the Scientific Advisory Committee
and Institutional Ethical Committee of Tuberculosis Research
Centre, Chennai. The recruitment of study subjects was done
between November 2007 and October 2008. All the study subjects
were informed about the study procedure and the volunteers were
assessed for this study. Individuals with previous history of TB,
those who underwent TST in the past 16 months, those with HIV
infection, silicosis, end stage renal disease, leukemia/lymphoma or
those under immunosuppressive therapy were excluded from the
study. Eligible subjects consenting to the study were recruited into
one of the following two groups.
(i) Healthy controls. This group consisted of healthy adult
subjects age ranged $18 years, apparently free of TB symptoms and
did not have close family contact of TB. All these subjects were
recruited from offices, colleges located at Chennai and near by
villages to Chennai. Since our setting is endemic to TB [25], to rule
out the suspicion of active TB disease, all the subjects were asked to
give three sputum samples and subjected to radiological examination.
(ii) Pulmonary TB (PTB) patients. This group consisted of
pulmonary TB patients who were recruited from Revised National
Tuberculosis Control Program (RNTCP) centers. The subjects
attending the RNTCP centre with the abnormalities, suggestive of
PTB in the chest X-ray and/or positive results for sputum
microscopy were assessed. Three sputum samples were collected
from all these study subjects and all were subjected to radiological
examination. The collected sputum samples were processed [26],
stained for acid fast bacilli (AFB) microscopy by Ziehl-Neelsen
method and cultured in Lowenstein Jensen (Biomerieux Inc.,
Marcy I’Etoile, France) and in liquid MP BacT medium
(Biomerieux Inc., Marcy I’Etoile, France). The presence of M.
tuberculosis in the positive culture samples was further confirmed
by Gen-probe based PCR (Biomerieux Inc., Marcy I’Etoile,
France) method. The presence of active TB was defined as positive
for sputum smear microscopy and/or positive for M. tuberculosis
in sputum culture and/or abnormality suggestive of TB in chest x-
ray. The patients with smear and culture negative results but had
abnormalities on chest x-ray, which was suggestive as TB, were
given broad spectrum antibiotics for three weeks. The non-
responders were then treated with anti-tuberculous therapy (ATT)
and followed up for at least two months. If the subject responded
to ATT, then he/she was considered as PTB patients as per
RNTCP guidelines [27].
Blood was drawn from all the recruited study subjects for total
blood count, HIV testing, random blood sugar levels, QFT-IT and
IP-10 assay. Then, the TST was carried out.
HIV Testing
The HIV status was confirmed by 2 rapid tests (Retroquic
Comb Aids-RS, Span Diagnostics, India and HIV TRI-DOT, J.
Mitra & Co, India). When a serum was positive for both tests, it
was considered as HIV positive. If a serum was positive for only
one EIA (which was rare), Western Blot was done as confirmatory
test.
Blood Sugar Levels
Random plasma glucose levels were measured by GOD-POD
method using Olympus AU 400 auto analyzer (Olympus GmbH,
Hamburg, Germany) with Olympus reagents. The normal range
for random blood sugar was considered as 80–140 mg/dl as per
kit instructions [28].
QFT-IT
The IFN-c release assay was performed using QFT-IT In-tube
test (Cellestis Ltd., Victoria, Australia). One ml of blood was taken
in each of the three tubes precoated with TB–antigen, phytohe-
maglutinin (PHA) for the positive control or no antigen for the
negative control. The blood samples were drawn between 10 and
11 AM and taken to the lab within 2 hours of phlebotomy. The
tubes were incubated for 16–24 hours at 37uC and plasma were
collected after centrifugation and stored at 4uC until assayed.
Within 2 weeks of time, QFT-IT enzyme linked immunosorbant
assay (ELISA) was carried out. The test results were interpreted
using software supplied by the manufacturer (Cellestis Ltd.,
Victoria, Australia) and the cut-off point for the diagnosis was
followed as per manufacturer’s instruction. If the IFN-c secretion
in response to TB antigen, after subtracting nil control IFN-c, was
$0.35 IU/ml, it was considered as positive for QFT-IT and if the
value was ,0.35 IU/ml, it was considered as negative. If the
negativity was associated with poor PHA response (i.e. IFN-c
secretion in response to PHA was ,0.5 IU/ml), it was considered
as indeterminate or invalid result for QFT-IT. The subjects with
IFN-c secretion .8.0 IU/ml in the nil control samples were also
considered as indeterminate for QFT-IT.
IP-10 Assay
The IP-10 levels were measured in duplicates in the supernatants
collected from QFT-IT tubes using BD opt EIA kits (BD
Biosciences, USA) as per manufacturer’s instructions [29]. Briefly,
100 ml of capture antibody (mouse anti human IP-10 monoclonal
antibody) at the recommended concentration was coated in the 96-
well flat bottom polystyrene plates (NUNC maxisorp, Roskilde,
Denmark). After overnight incubation, the excess antibodies were
washed off using PBST. The sample was added to the plate,
incubated for 2 hours and then the plates were washed off. The
secondary antibody (biotinylated anti human IP-10 monoclonal
antibody) conjugated with HRP was incubated for 1 hour and then
the excess antibodies were washed off. Then tetra methyl benzidine
(TMB) was used as substrate and incubated for 30 minutes and the
reaction was arrested by the addition of 2 N H2SO4.
Tuberculin Skin Test
The 2 TU (tuberculin unit) of purified protein derivative (PPD)
RT23 (Statens Serum Institute, Copenhagen, Denmark) was
injected intradermally by Mantoux method and the induration
was measured between 48–72 hrs after PPD injection by trained
Novel Tests in TB Diagnosis
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as 10 mm for this study.
Statistical Analysis
Data were analyzed using GraphPad Prism version 5.00 for
Windows (GraphPad Software, San Diego, California, USA) and
GraphPad software available in their website (www.graphpad.
com/quickcals.cfm). Kruskal-Wallis test was carried out to
calculate the differences of IFN-c and IP-10 levels between the
groups. The proportion of positivity between TST and QFT-IT or
IP-10 was compared using Fisher exact test. The comparison
between the QFT-IT and IP-10 was done by using McNemar Chi-
square tests, by treating the data as paired.
Results
A total of 277 study subjects were recruited during the study
period. There were 100 healthy controls and 177 PTB patients.
Blood was unavailable for 2 PTB patients. Tuberculin skin test
results were unavailable for 6 healthy controls and 58 (32.8%) PTB
patients.
All the subjects were negative for HIV infection and
demographic profile of those subjects is given in Table 1. All
the healthy controls were negative for sputum smear microscopy
and sputum culture. In PTB, sputum smear microscopy was
positive in 151 (85.3%) subjects and sputum culture was positive in
162 (91.5%) subjects. All the sputum smear positive cases were
positive for sputum culture.
Levels of IFN-c and IP-10
The levels of IP-10 in unstimulated plasma ranged 0–6975 pg/
ml (median 390 pg/ml) in healthy controls and 0–5973 pg/ml
(median 898 pg/ml) in PTB patients respectively. TB specific
antigens and mitogen stimulated significantly higher level of IP-10
secretion in healthy controls as well as TB patients (Figure 1).
Levels of IFN-c were also significantly higher in TB antigens as
well as mitogen stimulated samples than unstimulated samples of
healthy controls and PTB subjects (Figure 2).
Cut-Off Point Determination for IP-10
The antigen dependent IP-10 secretion was measured by
subtracting the level of IP-10 in nil tube from the TB antigen
coated tube. To determine the diagnostic performance of antigen
dependent IP-10 secretion, receiver-operator characteristic (ROC)
curve analysis was performed. QFT-IT and TST negative healthy
controls were considered as controls and culture positive PTB
patients were considered as diseased. It yielded 300 pg/ml as
optimum cut-off point for the antigen dependent IP-10 secretion
(p,0.0001). At this cut-off point, IP-10 showed 93.5% of specificity
Table 1. Demographic and baseline parameters of study
subjects.
Category HA PTB
Number of subjects 100 177
Sex, N (%)
Male 60 (60) 134 (75.7)
Female 40 (40) 43 (24.3)
Age, Median in years (Range; IQR) 29 (18–85; 22,50) 37 (18–70; 27,47)
Smear, N (%)
Positive 0 (0) 151 (85.3)
Negative 100 (100) 26 (14.7)
Culture, N (%)
Positive 0 (0) 162 (91.5)
Negative 100 (100) 15 (8.5)
Diabetes mellitus, N (%)
Present 0 (0) 20 (11.3)
Absent 100 (100) 157 (88.7)
X- ray results available, N (%) 100 (100) 157 (88.7)
Mild/moderate - 82 (52.2)
Extensive - 75 (47.8)
Cavity on chest x-ray, N (%) 157 (88.7)
Present - 32 (20.4)
Absent - 125 (79.6)
N - Number of subjects.
% - Percentage.
IQR - Inter quartile range.
HA - Healthy adults.
doi:10.1371/journal.pone.0009051.t001
Figure 1. The levels of IP-10 in unstimulated, TB antigens stimulated and mitogen stimulated samples of healthy controls (a) and
PTB patients (b). The levels of IP-10 in TB antigen stimulated and mitogen stimulated samples were significantly higher than unstimulated samples.
Box and Whisker plots show range, inter-quartile range and median. Nil – unstimulated; TB ag – TB antigens stimulated; mitogen- mitogen stimulated
samples. *significant difference p,0.05 by Kruskal- Wallis test.
doi:10.1371/journal.pone.0009051.g001
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0.946 (95% CI: 0.905–0.987). The 3 IP-10 positive subjects had IP-
10 secretion of 520 pg/ml and 1200 pg/ml and 5120 pg/ml in
response to TB specific antigens. The cut-off point for mitogen was
chosen as 200 pg/ml based on the earlier observation [11].
Hence, the IP-10 results were defined as follows; the subjects with
antigen dependent IP-10$300 pg/ml (TB antigen–nil), irrespective
of mitogen response were considered as positive; ,300 pg/ml for
antigen dependent IP-10 and $200 pg/ml for mitogen dependent
IP-10 were considered as negative; others (,300 pg/ml of antigen
dependent IP-10 for TB antigen and ,200 pg/ml of mitogen
dependent IP-10) were considered as indeterminate.
Sensitivity of QFT-IT, IP-10 and TST
Of 175 PTB tested, QFT-IT and IP-10 showed the sensitivities
of 88.6% (95%CI: 83.9–93.3%) and 91.4% (95%CI: 87.2–95.6%)
respectively. The indeterminate results were 2.3% (95%CI: 0–
4.5%) for QFT-IT and 1.2% (95%CI: 0–2.8%) for IP-10. When
the indeterminate results were excluded for sensitivity calculation,
QFT-IT and IP-10 yielded the diagnostic sensitivities of 90.6%
(95%CI: 86.3%–94.9%) and 92.5% (95%CI: 88.6%–96.4%)
respectively (Table 2). Of 119 results available, TST was positive
in 88 and 82 subjects at 5 mm and 10 mm cut-off points and
Figure 2. The levels of IFN-c in unstimulated, TB antigens stimulated and mitogen stimulated samples of healthy controls (a) and
PTB patients (b). The levels of IFN-c in TB antigen stimulated and mitogen stimulated samples were significantly higher that unstimulated samples.
Box and Whisker plots show range, inter-quartile range and median. Nil – unstimulated; TB ag – TB antigens stimulated; mitogen- mitogen stimulated
samples. *significant difference p,0.05 by Kruskal- Wallis test.
doi:10.1371/journal.pone.0009051.g002
Figure 3. ROC curve analysis for TB antigens specific IP-10. The
cut-off value for TB antigens specific IP-10 levels was determined by
using QFT-IT and TST negative healthy controls as uninfected and
culture confirmed TB patients as diseases subjects. The area under
curve was 0.946 (95% CI: 0.905–0.987). TB- tuberculosis; IP-10-Interferon
gamma inducible protein-10; QFT-IT – QuantiFERON-TB Gold in-tube;
TST – Tuberculin Skin test; CI-Confidence interval.
doi:10.1371/journal.pone.0009051.g003
Table 2. Positivity of QFT-IT, IP-10 and TST in active TB
patients.
Category Test N Pos Neg Indt % Sens
Total number of
subjects
QFT-IT 175 155 16 4 90.6
IP-10 175 160 13 2 92.5
TST 119 82 37 NA 68.9
Culture positives QFT-IT 160 141 15 4 90.4
IP-10 160 145 13 2 91.8
TST 110 75 35 NA 68.2
Culture negative QFT-IT 15 14 1 0 93.3
IP-10 15 15 0 0 100
TST 9 7 2 NA 77.8
Smear positive QFT-IT 149 133 12 4 91.7
IP-10 149 136 11 2 92.5
TST 104 73 31 NA 70.2
Smear negative QFT-IT 26 22 4 0 84.6
IP-10 26 24 2 0 92.3
TST 15 9 6 NA 60.0
10 mm cut-off point was used for TST.
N - Number of subjects.
QFT-IT - QuantiFERON-TB Gold.
IP-10 - Interferon gamma inducible protein-10.
TST - Tuberculin skin test.
Pos - Positive.
Neg - Negative.
Indt - Indeterminate.
% Sens - Percentage of sensitivity, calculated after excluding indeterminate
results.
doi:10.1371/journal.pone.0009051.t002
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68.9% (95%CI: 60.6%–77.2%) respectively. The sensitivity of
TST was lower than QFT-IT (p,0.001) and IP-10 (p,0.001) at
both 5 mm and 10 mm cut-off points. The positivity of IP-10 was
2.8% higher than QFT-IT; however, the difference between QFT-
IT and IP-10 did not reach statistical significance (p=0.383).
The sensitivities of all three tests were similar in culture positive
and negative cases (Table 2). A total of 26 subjects were negative
for smear microscopy and among them QFT-IT and IP-10
showed sensitivities of 84.6% and 92.3% respectively. TST results
were available for 15 subjects and its sensitivity was 73.3% and
60.0% at 5 mm and 10 mm cut-off points respectively.
Specificity of QFT-IT, IP-10 and TST
Of 100 healthy controls tested, none were indeterminate for
QFT-IT or IP-10. QFT-IT and IP-10 were positive in 45 and 52
healthy controls respectively (Table 3); hence, they yielded the
specificities of 55% (95% CI: 35.2%–54.8%) and 48% (95% CI:
38.2%–57.8%). Of 94 subjects tested for TB, TST was positive in
28 and 23 subjects at 5 mm and 10 mm cut-off points; hence
showed the specificities of 70.2% (95%CI: 61.0%–79.4%) and
75.5% (95% CI: 66.8%–84.2%) respectively.
Of 66 healthy controls with TST induration ,5 mm (consid-
ered to be uninfected), QFT-IT and IP-10 were positive in 21
(31.8%) and 24 (36.4%) subjects; hence showed the specificities of
68.2% and 63.6% respectively. In the 28 TST positive (at 5 mm
cut-off point) subjects, QFT-IT and IP-10 were positive in 24
(85.7%) and 22 (78.6%) subjects; hence showed the specificities of
14.3% and 21.4% respectively.
Influence of Diabetes Mellitus and Extent of Pulmonary
Involvement on the Sensitivity of Tests
We then analyzed the influence of the extent of pulmonary
involvement and presence of diabetes mellitus on the tests’
performance. Based on the radiological abnormalities, the patients
were classified into two categories; i) mild or moderate (lesions
found in #3 zones) ii) extensive (.3 zones) [30]. The sensitivities
of the tests remained similar in extensive and mild/moderate
cases. The presence of cavity or diabetes mellitus also did not
influence the sensitivities of any of the tests based on the statistical
analysis.
Combination of Tests
We further assessed whether the combination of tests will
improve their respective sensitivities. (Table 4). All the three test
results were available for 117 study patients. The sensitivities of
QFT-IT and IP-10 did not differ significantly between the overall
population (175 subjects; 89% and 91% respectively) and subjects
for whom three test results were available (117 subjects; 90% and
90% respectively).
Among 117 subjects, 11 (9.4%) were negative and 4 (3.4%)
were indeterminate for QFT-IT. All the 4 QFT-IT indetermi-
nate subjects were negative for TST. But 7/11 QFT-IT negative
subjects were positive for TST. Hence, in the combination with
TST, QFT-IT showed 93.2% (95%CI: 88.6%–97.8%) sensitiv-
ity and it was further increased to 96.5% (95%CI: 93.2%–
100%), when the indeterminate results (4 subjects; 2%) were
excluded.
We then analyzed the combination of IP-10 and TST. In the
117 subjects, 11 (9%) were negative and 2 (2%), indeterminate for
IP-10. Both the IP-10 indeterminate subjects were negative for
TST and 9 of the IP-10 negatives were positive for TST. Hence,
IP-10 with the combination of TST yielded a sensitivity of 96.6%
(95%CI: 93.3%–100%). Exclusion of indeterminate subjects (2
subjects; 1%) further enhanced the sensitivity to 98.3% (95%CI:
96%–100%). The combination of IP-10 and QFT-IT also failed to
detect 4 subjects; hence showed the sensitivity of 93.2% (95%CI:
88.6%–97.8%) and when the indeterminate results excluded, it
showed 96.5% (95%CI: 93.2%–100%).
When the combination of smear microscopy+TST+IP-10 used,
they could detect 100% of active TB patients. Smear microscopy +
TST + QFT-IT detected 98.2% (95%CI: 95.8%–100%) and
smear microscopy + QFT-IT + IP-10 detected 99.1% (95%CI:
97.4%–100%) subjects. On the other hand, the specificity of any of
two test combination was ,50%.
Discussion
This study reports that both QFT-IT and IP-10 were highly
sensitive in detecting active TB patients, but poorer in specificity
than TST. This is the first study evaluating IP-10 in subjects from
an endemic area and comparing it with QFT-IT and TST. The
Table 3. Positivity of QFT-IT, IP-10 and TST in healthy adult
subjects.
Tests N Pos Neg Indt % of Spec
QFT-IT 100 45 55 0 55
IP-10 100 52 48 0 48
TST 94 23 71 0 75.5
10 mm cut-off point was used for TST.
QFT-IT - QuantiFERON-TB Gold.
IP-10 - Interferon gamma inducible protein-10.
TST - Tuberculin skin test.
N - Number of subjects.
Pos - Positive.
Neg - Negative.
Indt - Indeterminate.
% Spec - Percentage of specificity, calculated after excluding indeterminate
results.
doi:10.1371/journal.pone.0009051.t003
Table 4. Analysis of combination of tests.
Tests % Sens (95% CI) % Spec (95% CI)
QFT-IT+TST 96.5 (93.2–100) 48.0 (38.0–58.0)
QFT-IT+TST+smear microscopy 98.2 (95.8–100) 48.0 (38.0–58.0)
IP-10+TST 98.3 (95.8–100) 44.8 (34.9–54.7)
IP-10+TST+smear microscopy 100.0 44.8 (34.9–54.7)
QFT-IT+IP-10 96.5 (93.2–100) 49.0 (39.0–59.0)
QFT-IT+IP-10+smear microscopy 99.1 (97.4–100) 49.0 (39.0–59.0)
10 mm cut-off point was used for TST.
Specificity was calculated as number of subjects negative for both the two tests
among the total number of healthy subjects, after excluding the indeterminate
results.
Sensitivity was calculated as number of subjects positive for either test among
PTB patients, after excluding the indeterminate results.
QFT-IT - QuantiFERON-TB Gold.
IP-10 - Interferon gamma inducible protein-10.
TST - Tuberculin skin test.
CI - Confidence interval.
% Sen - Percentage of sensitivity.
% spe - Percentage of specificity.
doi:10.1371/journal.pone.0009051.t004
Novel Tests in TB Diagnosis
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9051combination of QFT-IT or IP-10 with TST improved their
sensitivity.
Our study estimated the sensitivity of QFT-IT as being higher
than the reported range in the earlier studies from high endemic
countries [31]. The probable reasons for obtaining lower
sensitivity for IGRA in high burden countries include HIV co-
infection, advanced disease, malnutrition, host immune response
and variation in the M. tuberculosis strain [31]. In most of the studies
conducted in high burden countries, HIV positive subjects were
included [14,16] or HIV status of the study patients was unknown
[15]. HIV is the one of the major influencing factors of
performance of QFT-IT [32]. Our earlier study also reported
the reduced sensitivity of QFT-IT in detecting active TB cases
among HIV positive individuals [33]. Exclusion of HIV patients in
our study may be one of the reasons for obtaining higher sensitivity
for QFT-IT in contrast to earlier studies. Apart from that, the
effect of genetic makeup in the population and variation in the
infecting M. tuberculosis strains may also be alternative reasons for
obtaining higher sensitivity for QFT-IT in our study than the
earlier reports [34]. However, further studies are needed to
confirm this aspect.
The higher levels of IP-10 were shown in serum and pleural
fluid from the TB patients [35–37]. More recently, it was shown
that secretion of IP-10 was significantly induced upon stimulation
with TB specific antigens and thus also suggested as alternative
marker for LTBI diagnosis [11,17–20]. In this study, we found
that the sensitivity of IP-10 was 2.8% higher than QFT-IT and
showed less indeterminate results. IP-10 is secreted in larger
quantity in response to antigens and even a small quantity of
IFN-c is enough to induce the secretion of larger quantity of IP-10
[21,22]. A recent study conducted in Denmark population also
reported that IP-10 is a potential diagnostic marker [11].
Considering the lesser number of indeterminate results and higher
sensitivity of IP-10, we suggest using IP-10 as an alternative
biomarker for the diagnosis of M. tuberculosis infection particularly
where QFT-IT fails; however the utility of IP-10 would be limited
by its poor specificity.
The production of IFN-c was correlated with radiological
extent of pulmonary involvement in the earlier studies [38,39].
The secretion of IFN-c was significantly lower in patients with
far advanced radiological extent of pulmonary TB, than
subjects with minimal or moderate, upon stimulation with
PHA or M. tuberculosis strain. However, our study results
suggested that the sensitivities of QFT-IT and IP-10 were not
affected by radiological extent of pulmonary involvement.
Diabetes mellitus is another co-morbid condition for TB
patients and suppresses the expression of Th1 related cytokines
[40,41]. Hence, it is expected to be an influencing factor in
immune based tests; however the trend was not observed in our
study results.
The poor specificities of QFT-IT, IP-10 and TST obtained in
this study were expected, due to the high number of LTBI cases in
our setting. When the specificities of QFT-IT and IP-10 were
compared between TST negative healthy controls and TST
positive healthy controls, the specificities of both tests were higher
in the former group (data not shown). This reflects the higher
positivities of QFT-IT and IP-10 obtained in healthy controls due
to the high number of latently infected cases.
It is reported in the earlier studies that discordance between
TST and QFT-IT results were often observed [12,42]. Taking this
as an advantage, earlier studies have investigated whether the
sensitivity of QFT-IT or ELISPOT have been improved when
combined with TST. We applied the same approach to our data
and then analyzed the sensitivity and specificity of various
combinations.
We could obtain almost 90% sensitivity using QFT-IT or IP-10
alone. The analysis of different combinations showed that IP-10
and TST can detect more than 98% of active TB patients. In TB
endemic countries, smear microscopy is the primary diagnostic
tools to diagnose active TB patients. Any test which complements
smear microscopy is highly needed in the current situation in low
resource settings. Hence, we assessed whether QFT-IT, IP-10 and
TST improved the sensitivity of smear microscopy. If the smear
microscopy was also included in the combination, it reached 100%
sensitivity. Even the other combinations like QFT-IT, TST and
smear microscopy or QFT-IT, IP-10 and TST also reached
.98% sensitivity.
Our study has some limitations. In this study the TST results
were not available for 32.8% of PTB patients. Unexpectedly, some
of the study subjects did not turn up for the TST reading. But, it
unlikely influenced the performance of TST. When the subjects
with TST results and without were compared, there was no
significant difference observed between two groups in the
demographic profile, severity of TB disease and sensitivities of
QFT-IT and IP-10. In this study, we included only pulmonary TB,
but not extra pulmonary TB patients. However, in our earlier study
[33], we evidenced that the sensitivity of QFT-IT was similar in
pulmonary and extra pulmonary TB patients. In this study, we did
not include HIV positive TB patients. TB is the commonest
opportunistic infection among HIV infected individuals and the
progression ofTBinfectionalsoisrapid[43].Sincetheperformance
immunebased diagnostictestsareexpected to be attenuated inHIV
infected individuals, it is time to propose different tests for HIV
positive and negative individuals. After the introduction of
Integrated Counseling and Testing Centre (ICTC), it is becoming
a policy that TB suspected individuals have to be screened for HIV
infection also and vice versa [44]. In this situation, it is possible to
imply different tests for HIV positive and negative population. In
addition, the prevalence of HIV infection among TB patients is low
(5%) in our settings in contrast to the status in sub-Saharan African
countries where 80% of TB patients were co-infected with HIV
[45].
Overall, we conclude that QFT-IT and IP-10 have higher
sensitivity in diagnosing the active TB cases among HIV
seronegative individuals. The combination of TST, QFT-IT
and IP-10 showed .95% sensitivity. The higher sensitivity of
combination of QFT-IT/IP-10 and TST suggests that they may
be useful in active TB diagnosis as supplement marker along
with existing diagnostic tools. However their role is limited by
their poor specificity due to the high prevalence LTBI in our
setting.
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